Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS) and generally spreads to the nearby brain tissues. Its symptoms include seizures, constant headaches, vomiting, blurred or double vision, and difficulty in speaking.

A key factor contributing to growth of the glioblastoma multiforme market is the rising number of brain and other nervous system cancers occurring worldwide. Globally, GBM accounted for 54% of new gliomas and 45% of primary malignant tumors. According to the U.S National Cancer Institute 2015 estimates 22,850 adults comprising 10,280 women and 12,630 men were diagnosed with brain and other forms of nervous system cancer. The rising number of cases of GBM is expected to drive the glioblastoma multiforme market during the forecast period. Increase in funding for companies involved in the research on GBM is also contributing to the growth of the glioblastoma multiforme market. For instance, in February 2018, Novocure announced that it would receive fresh infusion of capital from BioPharma Credit PLC, which is an investment fund of Pharmakon Advisors, LP. The term loan agreement for US$ 150 Mn will be used by Novocure to accelerate its R&D on improved treatment option for GBM. Additionally, companies are focusing on the development of new drugs and therapies in order to maintain their competitive advantage and penetrate new regional markets. In December 2017, Genentech, a subsidiary of Roche, announced that it had received approval from U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab) to be used in the treatment glioblastoma in adults. In September 2017, the FDA approved Amgen’s MVASI (bevacizumab-awwb), which is the first bevacizumab biosimilar as well as the first anti-cancer biosimilar to be approved for the treatment of five types of cancer, including GBM. In July 2016, Mylan launched Temozolomide capsules, the generic version of Merck’s Temodar, in the U.S. The capsules are indicated for use concomitantly with radiotherapy in adult patients for the treatment of glioblastoma multiforme.

The glioblastoma multiforme market can be segmented based on treatment type, end-user, and geography. In terms of treatment type, the market can be divided into drugs, electric-field therapy, and others. The drugs segment can be further divided into antineoplastic agents, anticonvulsants, and corticosteroids. Based on end-user, the glioblastoma multiforme market can be classified into hospitals, ambulatory surgical centers, and specialty clinics.

Geographically, the global glioblastoma multiforme market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global glioblastoma multiforme market due to rise in funding for research & development of novel drugs and therapies for the treatment of glioblastoma. North America is followed by Europe and Asia Pacific. Grant of regulatory approval for new treatment therapies for glioblastoma is propelling the growth of the glioblastoma multiforme market in Asia Pacific. In December 2017, the Ministry of Health, Labour and Welfare in Japan approved the recommendation of the Central Social Insurance Medical Council (Chuikyo) for providing reimbursement for Novocure’s Optune, which is a non-invasive, portable device used in the treatment of newly diagnosed glioblastoma.

Prominent players operating in the global glioblastoma multiforme market are Bexion Pharmaceuticals, LLC, Bristol-Myers Squibb, Double Bond Pharmaceutical, Diffusion Pharmaceuticals, F. Hoffmann-La Roche AG., GW Pharmaceuticals, plc. Merck & Co., Inc., MimiVax, LLC, Novocure, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Glioblastoma Multiforme (GBM) Market